Clinical Trials Logo

Urothelial Bladder Cancer clinical trials

View clinical trials related to Urothelial Bladder Cancer.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT04779151 Suspended - Clinical trials for Head and Neck Cancer

Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab

NIRADO
Start date: April 7, 2021
Phase: Phase 2
Study type: Interventional

Treatment will consist of a PARP inhibitor (niraparib) monotherapy priming period (cycle 0; 21 days); an anti-PD-1 antibody (Dostarlimab ; TSR-042) will then be added from C1D1 every 21 days in combination for the first 4 cycles, and then every 42 days. Disease will be assessed every 2 cycles (6 weeks) from C3D1 by CT-scan (or MRI or bone scan, if relevant). Patients still under treatment after 1 year may have tumor evaluation spaced out every 3 cycles